Loading ...

TOPLINE:

Hidradenitis suppurativa (HS) is associated with an increased risk for cardiovascular comorbidities in a meta-analysis, with hypertension affecting approximately one quarter of patients.

METHODOLOGY:

• Researchers conducted a systematic review and meta-analysis of 25 studies comprising 373,689 people with HS.
• Outcomes included cardiovascular comorbidity prevalence (24 studies) and cardiovascular outcomes (17 studies) among individuals with HS compared with control populations without the disease.
• Study designs included population registry cohorts (eight), single-center clinical samples (seven), electronic health record network datasets (five), claims databases (four), and one inpatient database study from various geographic locations.

TAKEAWAY:

• Hypertension was the most common cardiovascular comorbidity, with a pooled prevalence of 25.6% among individuals with HS. Cerebrovascular disease affected 2.2% of patients, congestive heart failure affected 1.9%, coronary heart disease affected 4.2%, and myocardial infarction affected 1.9% of patients with HS.
• HS was associated with an increased odds of hypertension (odds ratio [OR], 1.52; 95% CI, 1.29-1.80) across seven studies reporting odds ratios.
• Patients with HS demonstrated elevated relative risks for congestive heart failure (relative risk [RR], 1.85; 95% CI, 1.44-2.38), coronary or ischemic heart disease (RR, 1.75; 95% CI, 1.59-1.92), composite cardiovascular disease (RR, 1.30; 95% CI, 1.15-1.46), myocardial infarction (RR, 1.51; 95% CI, 1.22-1.88), and venous thromboembolism (RR, 1.72; 95% CI, 1.47-2.02%).
• The risk for all-cause mortality was higher among individuals with HS (RR, 1.86; 95% CI, 1.10-3.12) than among populations without HS.

IN PRACTICE:

The study “reinforces the emerging view of HS as a systemic inflammatory disease with potential cardiovascular implications and supports further investigation into the contribution of systemic inflammation to cardiovascular risk,” the authors of the study wrote. The results, they added, “support consideration of routine cardiovascular risk assessment and management of modifiable cardiometabolic risk factors as part of comprehensive HS care.”

SOURCE:

The study was led by Sophia A. Mense, Rush University Medical College, Chicago, and was published online on May 11 in the British Journal of Dermatology.

LIMITATIONS:

Limitations included the observational design of included studies, limiting causal inference and high heterogeneity.

DISCLOSURES:

The study received no specific funding. One author disclosed serving as an advisor, consultant, speaker, and/or investigator for multiple pharmaceutical and biotechnology companies including AbbVie; Acelyrin Inc.; Alumis Inc.; Amgen, and AnaptysBio, Inc.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.